Skip Navigation LinksHome > January 2014 - Volume 20 - Issue 1 > Efficacy of Hepatitis A Vaccination and Factors Impacting on...
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000437736.91712.a1
Original Clinical Articles

Efficacy of Hepatitis A Vaccination and Factors Impacting on Seroconversion in Patients with Inflammatory Bowel Disease

Park, Sang Hyoung MD*; Yang, Suk-Kyun MD*; Park, Soo-Kyung MD*; Kim, Jong Wook MD*,†; Yang, Dong-Hoon MD*; Jung, Kee Wook MD*; Kim, Kyung-Jo MD*; Ye, Byong Duk MD*; Byeon, Jeong-Sik MD*; Myung, Seung-Jae MD*; Kim, Jin-Ho MD*

Collapse Box

Abstract

Background:

Little is known about the immune response to hepatitis A virus (HAV) vaccinations in patients with inflammatory bowel disease (IBD). We therefore assessed the immunogenicity of HAV vaccine in patients with IBD and evaluated the impact on vaccination efficacy of immunosuppressants, including corticosteroids, thiopurines, and anti–tumor necrosis factor (anti-TNF) agents.

Methods:

This open prospective study evaluated the efficacy of HAV vaccination in 419 anti–HAV-negative adult patients with IBD. Patients were vaccinated against HAV at 0 and 6 to 12 months, with seroconversion (anti-HAV immunoglobulin G) measured 1 to 3 months after the second dose.

Results:

Of the 419 vaccinated patients who finished the study protocol (mean age, 26.9 yr), 355 (84.7%) had Crohn's disease and 64 (15.3%) had ulcerative colitis. The overall seroconversion rate was 97.6% (409/419) but was significantly lower in patients treated with the anti-TNF monoclonal antibody infliximab or adalimumab than in those not treated (92.4% [85/92] versus 99.1% [324/327], P = 0.001). In addition, the seroconversion rate was significantly lower in patients treated with ≥2 than with <2 immunosuppressants (92.6% [50/54] versus 98.4% [359/365], P = 0.03). When comparing anti-TNF alone with anti-TNF and other immunosuppressants, there was no significant difference in seroconversion rates (odds ratio, 1.2; 95% confidence interval, 0.2–5.6; P = 0.83). The sample/cutoff ratio was significantly lower in patients who did receive anti-TNF therapy than in those who did not (5.5 versus 9.6; P < 0.001).

Conclusions:

Although HAV vaccination is generally effective in patients with IBD, the seroconversion rate is lower in patients receiving anti-TNF agents ( ClinicalTrials.gov registration number NCT01341808).

Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.